TY - JOUR
T1 - Classifying atopic dermatitis
T2 - a systematic review of phenotypes and associated characteristics
AU - Bosma, A. L.
AU - Ascott, A.
AU - Iskandar, R.
AU - Farquhar, K.
AU - Matthewman, J.
AU - Langendam, M. W.
AU - Mulick, A.
AU - Abuabara, K.
AU - Williams, H. C.
AU - Spuls, P. I.
AU - Langan, S. M.
AU - Middelkamp-Hup, M. A.
N1 - Funding Information: ALB, PIS, SML and MAMH are investigators on the European Union Horizon 2020‐funded BIOMAP Consortium ( http://www.biomap‐imi.eu/ ). KA received grants for investigator‐initiated research to her institution from NIH, National Eczema Foundation, LEO Foundation, Pfizer and Cosmetique International and consulting fees from TARGET RWE. PIS has done consultancies in the past for Sanofi 111017 and AbbVie 041217 (unpaid), receives departmental independent research grants for TREAT NL registry, for which she is Chief Investigator (CI), from different pharma companies since December 2019, is involved in performing clinical trials with many pharmaceutical industries that manufacture drugs used for the treatment, e.g. psoriasis and atopic dermatitis, for which financial compensation is paid to the department/hospital. SML received grants from Wellcome Trust and the Innovative Medicine Initiative Horizon 2020 (BIOMAP project) payed to her institution. AM received a grant from Wellcome Trust payed to her institution. No other disclosures were reported. Funding Information: ALB, PIS and PMH were supported by departmental resources. SML was supported by a Wellcome Trust Senior Research Fellowship in Clinical Science (205039/Z/16/Z). The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the funders. Publisher Copyright: © 2022 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology
PY - 2022/6/1
Y1 - 2022/6/1
N2 - Atopic dermatitis is a heterogeneous disease, accompanied by a wide variation in disease presentation and the potential to identify many phenotypes that may be relevant for prognosis and treatment. We aimed to systematically review previously reported phenotypes of atopic dermatitis and any characteristics associated with them. Ovid EMBASE, Ovid MEDLINE and Web of Science were searched from inception till 12 February 2021 for studies attempting to classify atopic dermatitis. Primary outcomes are atopic dermatitis phenotypes and characteristics associated with them in subsequent analyses. A secondary outcome is the methodological approach used to derive them. In total, 8511 records were found. By focussing only on certain clinical phenotypes, 186 studies were eligible for inclusion. The majority of studies were hospital-based (59%, 109/186) and cross-sectional (76%, 141/186). The number of included patients ranged from seven to 526 808. Data-driven approaches to identify phenotypes were only used in a minority of studies (7%, 13/186). Ninety-one studies (49%) investigated a phenotype based on disease severity. A phenotype based on disease trajectory, morphology and eczema herpeticum was investigated in 56 (30%), 22 (12%) and 11 (6%) studies respectively. Thirty-six studies (19%) investigated morphological characteristics in other phenotypes. Investigated associated characteristics differed between studies. In conclusion, we present an overview of phenotype definitions used in literature for severity, trajectory, morphology and eczema herpeticum, including associated characteristics. There is a lack of uniform and consistent use of atopic dermatitis phenotypes across studies.
AB - Atopic dermatitis is a heterogeneous disease, accompanied by a wide variation in disease presentation and the potential to identify many phenotypes that may be relevant for prognosis and treatment. We aimed to systematically review previously reported phenotypes of atopic dermatitis and any characteristics associated with them. Ovid EMBASE, Ovid MEDLINE and Web of Science were searched from inception till 12 February 2021 for studies attempting to classify atopic dermatitis. Primary outcomes are atopic dermatitis phenotypes and characteristics associated with them in subsequent analyses. A secondary outcome is the methodological approach used to derive them. In total, 8511 records were found. By focussing only on certain clinical phenotypes, 186 studies were eligible for inclusion. The majority of studies were hospital-based (59%, 109/186) and cross-sectional (76%, 141/186). The number of included patients ranged from seven to 526 808. Data-driven approaches to identify phenotypes were only used in a minority of studies (7%, 13/186). Ninety-one studies (49%) investigated a phenotype based on disease severity. A phenotype based on disease trajectory, morphology and eczema herpeticum was investigated in 56 (30%), 22 (12%) and 11 (6%) studies respectively. Thirty-six studies (19%) investigated morphological characteristics in other phenotypes. Investigated associated characteristics differed between studies. In conclusion, we present an overview of phenotype definitions used in literature for severity, trajectory, morphology and eczema herpeticum, including associated characteristics. There is a lack of uniform and consistent use of atopic dermatitis phenotypes across studies.
UR - http://www.scopus.com/inward/record.url?scp=85125232821&partnerID=8YFLogxK
U2 - https://doi.org/10.1111/jdv.18008
DO - https://doi.org/10.1111/jdv.18008
M3 - Review article
C2 - 35170821
SN - 0926-9959
VL - 36
SP - 807
EP - 819
JO - Journal of the European Academy of Dermatology and Venereology
JF - Journal of the European Academy of Dermatology and Venereology
IS - 6
ER -